Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.

Pochamana Phisalprapa,Chayanis Kositamongkol,Julajak Limsrivilai,Satimai Aniwan,Phunchai Charatcharoenwitthaya,Pises Pisespongsa,Taya Kitiyakara,Suporn Treepongkaruna,Nathorn Chaiyakunapruk

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.

2020

Pochamana Phisalprapa
Chayanis Kositamongkol
Julajak Limsrivilai
Satimai Aniwan
Phunchai Charatcharoenwitthaya
Pises Pisespongsa
Taya Kitiyakara
Suporn Treepongkaruna
Nathorn Chaiyakunapruk

Aims: This study aimed to conduct a cost-effectiveness analysis of infliximab and its biosimilar compared to conventional therapy in refractory moderate-to-severe Crohn’s disease (CD) in Thailand.M...

Keywords:

Infliximab
Intensive care medicine
in patient
Cost-effectiveness analysis
Crohn's disease
Medicine
Refractory
Disease
Biosimilar
cost effectiveness

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations